Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2020/08/027345
CTRI/2020/08/027345
Not yet recruiting
Phase 3

Selection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients: A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trial

Pt B D Sharma post graduate institute of medical sciences0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Pt B D Sharma post graduate institute of medical sciences
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Pt B D Sharma post graduate institute of medical sciences

Eligibility Criteria

Inclusion Criteria

  • •Adult patients with COVID\-19 aged 18 years and above
  • •RT\-PCR positive for SARS\-CoV\-2
  • •Willing to give written informed consent

Exclusion Criteria

  • •Pregnancy or breast feeding
  • •Hepatic cirrhosis
  • •Alanine aminotransferase or aspartate aminotransferase more than five times the upper limit of normal
  • •Known severe renal impairment (estimated glomerular filtration rate \<30 mL/min per 1·73 m2\) or receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis
  • •Enrolment into an investigational treatment study for COVID\-19 in the 30 days before screening
  • •Patients of child\-bearing age (men and women) not agreeing to take effective contraceptive measures (including hormonal contraception, barrier methods, or abstinence) during the study period and for at least 7 days after the last study drug administration
  • •Any known hypersensitivity to the study drugs
  • •Any patient belonging to Severe class of COVID19 disease as per GOI guidelines (MoHFW)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Antiviral therapy with direct acting anti-virals in hepatitis C patients.Chronic hepatitis C
JPRN-UMIN000016288Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine500
Recruiting
Not Applicable
Establish a new algorithm for antiviral therapies based on HCV NS5A mutation status in patients with chronic hepatitis C infection.patients with chronic hepatitis C infection
JPRN-UMIN000018942agoya University230
Completed
Not Applicable
The effect of generic drugs in treatment of chronic hepatitis C patients
IRCT2017020210417N6Kermanshah University of Medical Sciences60
Recruiting
Not Applicable
Optimization of Antiviral Treatments for Chronic Hepatitis B to Improve Clinical OutcomesCertain infectious and parasitic diseases
KCT0002039Asan Medical Center10,000
Completed
Not Applicable
study with HIV-HBV coinfected patients.Health Condition 1: null- HIV/HBV co infected ART naive and experienced patients.
CTRI/2012/03/002471Calcutta School of Tropical Medicine68